Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF~* Patients with elevated LCI of ≥ 7.5 at screening~* Patients with FEV1 of ≥ 50% predicted at screening~* Use of inhaled Tobramycin in a 28 days on / off regimen in the past 3 months before screening~* chronic lung Infection with Pseudomonas aeruginosa~Exclusion Criteria:~* Patients who are regularly receiving more than one class of inhaled anti-pseudomonal antibiotic~* Patients who have used oral or intravenous anti-pseudomonal antibiotics within 28 days prior to on-phase of study drug~* Pregnant or nursing (lactating) women~* Change in dose, formulation or strength of the study drug in the past treatment cycle before screening~* History of hearing loss or chronic tinnitus~* Infection with Burkholderia cenocepacia complex~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin ALL (Type: EXPERIMENTAL): 300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off

Based on this trial design, predict the completion outcome and termination type (if applicable).